Steve R Martinez1, Keira L Barr, Robert J Canter. 1. Division of Surgical Oncology, Department of Surgery, UC Davis Cancer Center, 4501 X St, Ste 3010, Sacramento, CA 95817, USA. steve.martinez@ucdmc.ucdavis.edu
Abstract
OBJECTIVE: To identify prognostic factors related to malignant cutaneous adnexal tumors. DESIGN: Population-based study using the Surveillance, Epidemiology, and End Results database from January 1, 1988, through December 31, 2006. SETTING: Seventeen population-based cancer registries. PARTICIPANTS: A total of 4032 patients with malignant cutaneous adnexal tumors. MAIN OUTCOME MEASURES: Overall survival (OS) and disease-specific survival (DSS). RESULTS: Ten-year OS and DSS rates were 54% and 97%, respectively. Unfavorable factors for OS were increasing age (hazard ratio [HR] 1.08; 95% confidence interval [CI], 1.07-1.09; P < .001), distant metastases (3.26; 2.34-4.53; P < .001), no surgical procedure (1.27; 1.01-1.59; P = .04), grade IV tumors (1.97; 1.18-3.28; P = .009), nodal metastases (2.19; 1.40-3.43; P = .001), and T3 tumors (1.37; 1.00-1.87; P = .04). Favorable factors for OS were a wide surgical excision (HR, 0.78; 95% CI, 0.68-0.89; P < .001), female sex (0.73; 0.65-0.82; P < .001), malignant eccrine spiradenoma (0.72; 0.53-0.99; P = .04), and histologic findings of sweat duct carcinoma (0.63; 0.44-0.90; P = .01). Unfavorable factors for DSS included N1 status (HR, 6.77; 95% CI, 2.11-21.68; P < .001), distant metastases (12.24; 6.03-24.85; P < .001), histologic findings of malignant eccrine spiradenoma (5.62; 1.25-25.34; P = .02), and no surgical procedure (2.81; 1.09-7.23; P = .03). Favorable factors for DSS included female sex (HR, 0.52; 95% CI, 0.30-0.91; P = .02). CONCLUSIONS: Five-year survival among patients with malignant cutaneous adnexal tumors is good in the absence of distant metastases. Wide resection may be preferable to less aggressive excision. The prognostic importance of lymph node metastases warrants consideration of lymph node basin staging.
OBJECTIVE: To identify prognostic factors related to malignant cutaneous adnexal tumors. DESIGN: Population-based study using the Surveillance, Epidemiology, and End Results database from January 1, 1988, through December 31, 2006. SETTING: Seventeen population-based cancer registries. PARTICIPANTS: A total of 4032 patients with malignant cutaneous adnexal tumors. MAIN OUTCOME MEASURES: Overall survival (OS) and disease-specific survival (DSS). RESULTS: Ten-year OS and DSS rates were 54% and 97%, respectively. Unfavorable factors for OS were increasing age (hazard ratio [HR] 1.08; 95% confidence interval [CI], 1.07-1.09; P < .001), distant metastases (3.26; 2.34-4.53; P < .001), no surgical procedure (1.27; 1.01-1.59; P = .04), grade IV tumors (1.97; 1.18-3.28; P = .009), nodal metastases (2.19; 1.40-3.43; P = .001), and T3 tumors (1.37; 1.00-1.87; P = .04). Favorable factors for OS were a wide surgical excision (HR, 0.78; 95% CI, 0.68-0.89; P < .001), female sex (0.73; 0.65-0.82; P < .001), malignant eccrine spiradenoma (0.72; 0.53-0.99; P = .04), and histologic findings of sweat duct carcinoma (0.63; 0.44-0.90; P = .01). Unfavorable factors for DSS included N1 status (HR, 6.77; 95% CI, 2.11-21.68; P < .001), distant metastases (12.24; 6.03-24.85; P < .001), histologic findings of malignant eccrine spiradenoma (5.62; 1.25-25.34; P = .02), and no surgical procedure (2.81; 1.09-7.23; P = .03). Favorable factors for DSS included female sex (HR, 0.52; 95% CI, 0.30-0.91; P = .02). CONCLUSIONS: Five-year survival among patients with malignant cutaneous adnexal tumors is good in the absence of distant metastases. Wide resection may be preferable to less aggressive excision. The prognostic importance of lymph node metastases warrants consideration of lymph node basin staging.
Authors: Hanneke Stam; Bart A van de Wiel; W Martin C Klop; Biljana Zupan-Kajcovski; Soe Janssens; M Baris Karakullukcu; Vincent van der Noort; Peter J F M Lohuis Journal: Eur Arch Otorhinolaryngol Date: 2014-10-16 Impact factor: 2.503
Authors: Carlos Prieto-Granada; Nicholas Castner; Ann Chen; Jiannong Li; Binglin Yue; Joyce Y Wong; Sanjana Iyengar; Vernon K Sondak; Jonathan S Zager; Jane L Messina Journal: Pathol Oncol Res Date: 2018-06-14 Impact factor: 3.201
Authors: Daniel H Miller; Jennifer L Peterson; Steven J Buskirk; Laura A Vallow; Randy Ta; Richard Joseph; Murli Krishna; Stephen J Ko; Katherine S Tzou Journal: Rare Tumors Date: 2015-10-05
Authors: Dulce M Barrios; Mytrang H Do; Gregory S Phillips; Michael A Postow; Tomoko Akaike; Paul Nghiem; Mario E Lacouture Journal: J Am Acad Dermatol Date: 2020-05-24 Impact factor: 11.527